Reduced Cerebrospinal Fluid Levels of Lysophosphatidic Acid Docosahexaenoic Acid in Patients With Major Depressive Disorder and Schizophrenia
| Autor: | Junken Aoki, Kotaro Hattori, Mami Tsuchioka, Hiroshi Kunugi, Minoru Takebayashi, Wataru Omori, Kuniyuki Kano, Shuken Boku, Naoto Kajitani |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Regular Research Articles chemistry.chemical_compound 0302 clinical medicine Cerebrospinal fluid Japan Lysophosphatidic acid Pharmacology (medical) AcademicSubjects/SCI01870 Middle Aged docosahexaenoic acid Pathophysiology Psychiatry and Mental health Docosahexaenoic acid Schizophrenia Major depressive disorder Female lipids (amino acids peptides and proteins) biological phenomena cell phenomena and immunity medicine.symptom Autotaxin Adult medicine.medical_specialty Docosahexaenoic Acids AcademicSubjects/MED00415 Inflammation behavioral disciplines and activities 03 medical and health sciences Internal medicine mental disorders medicine Humans Pharmacology Depressive Disorder Major major depressive disorder Phosphoric Diester Hydrolases business.industry medicine.disease schizophrenia 030104 developmental biology Endocrinology chemistry Case-Control Studies Lysophospholipids business lysophosphatidic acid 030217 neurology & neurosurgery Chromatography Liquid |
| Zdroj: | International Journal of Neuropsychopharmacology |
| ISSN: | 1469-5111 1461-1457 |
| Popis: | Background Lysophosphatidic acid (LPA) is involved in numerous biological processes, including neurodevelopment, chronic inflammation, and immunologic response in the central nervous system. Autotaxin (ATX) is a secreted enzyme that produces LPA from lysophosphatidylcholine (LPC). Previous studies have demonstrated decreased protein levels of ATX in cerebrospinal fluid (CSF) of patients with major depressive disorder (MDD). Based on those studies, the current study investigated the levels of lysophospholipids species including LPA and related metabolic enzymes, in CSF of patients with MDD and schizophrenia (SCZ). Methods The levels of lysophospholipids species and related metabolic enzymes were measured with either liquid chromatography-tandem mass spectrometry or enzyme-linked immunosorbent assay. Japanese patients were diagnosed with DSM-IV-TR. CSF was obtained from age- and sex-matched healthy controls (n = 27) and patients with MDD (n = 26) and SCZ (n = 27). Results Of all lysophospholipids species, the levels of LPA 22:6 (LPA - docosahexaenoic acid) were significantly lower in patients with MDD and SCZ than in healthy controls. These levels were negatively correlated with several clinical symptomatic scores of MDD, but not those of SCZ. In addition, the levels of LPA 22:6 were significantly correlated with the levels of LPC 22:6 among all 3 groups. On the other hand, the levels of LPA 22:6 were not correlated with ATX activity in patients with MDD and SCZ. Conclusion The lower levels of LPA 22:6 in patients with MDD and SCZ suggest an abnormality of LPA 22:6 metabolism. In addition, several depressive symptoms in patients with MDD were significantly associated with the lower levels of LPA 22:6, suggesting an involvement of LPA 22:6 in the pathophysiology of MDD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|